Evidence map›Paper›PMID 30465182›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.

M Bloemendal, M J A Rietveld, W W van Willigen, W R Gerritsen, C G Figdor, J J Bonenkamp, H Westdorp, S Boudewijns, R H T Koornstra, E M M Adang and 4 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

M BloemendalDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-9395-4214
M J A RietveldDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-7780-1250
W W van WilligenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
W R GerritsenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
C G FigdorDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-2366-9212
J J BonenkampDepartment of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-3608-4184
H WestdorpDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-3336-4164
S BoudewijnsDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-4201-3507
R H T KoornstraDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-5446-755X
E M M AdangDepartment of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-4773-6176
G SchreibeltDepartment of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-0156-8365
P B OttevangerDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-8209-487X
I J M de VriesDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. jolanda.devries@radboudumc.nl.ORCID http://orcid.org/0000-0002-8653-4040
K F BolDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-4165-2040
Radboud University Nijmegen · NL

Funding

H2020 European Research Council advanced grant PATHFINDER 269019KWF Kankerbestrijding 2009-4402Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NL) Spinoza grantNederlandse Organisatie voor Wetenschappelijk Onderzoek (NL) Vici grant (918.14.655)
6 · The paper itself

Abstract

backgroundHealth-related quality of life (HRQoL) is an important issue in the rapidly evolving field of adjuvant treatment for stage III melanoma. Dendritic cell vaccination is one of the adjuvant forms of therapy currently investigated.

methodsWe enrolled adults with stage III melanoma to receive adjuvant dendritic cell vaccination after a complete radical lymph node dissection. HRQoL assessment was one of the secondary endpoints of this trial and investigated with the EORTC-QLQ-C30 questionnaire at baseline and week 26.

resultsFifteen patients with a median age of 50 years were included in the study, with twelve evaluable patients on study at time of the second questionnaire. Global health status and role functioning improved clinically relevant with a mean difference of 15 (p = 0.010) and 26 points (p = 0.005), respectively. DISCUSSION: Despite the small number of patients, we found a clinically relevant improved global health status. Besides, compared to the other investigated therapies, toxicity of dendritic cell vaccination is low, which supports our finding.

conclusionThis is the first description of HRQoL in melanoma patients receiving dendritic cell vaccination. We show the expected improvement in global health status after surgical treatment of stage III melanoma. Thus, adjuvant dendritic cell vaccination does not seem to hamper this improvement, as shown in our small explorative study.

Indexed as

ImmunotherapyQuality of LifeAdjuvants, ImmunologicAdultAgedDendritic CellsFemaleFollow-Up StudiesHumansMaleMelanomaMiddle AgedNeoplasm StagingProspective StudiesSurveys and QuestionnairesYoung AdultAdjuvants, ImmunologicAdjuvant therapyCancerDendritic cell vaccinationImmunotherapyMelanomaStage III melanoma

Identifiers

PMID30465182
OpenAlexW2901743875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.